Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2010035 | 0.93 | — | — | |
| SCHEMBL6311231 | 0.88 | CXCR4 (0.50) | CXCR4SMN1; SMN2KEAP1SIGMAR1 | |
| SCHEMBL1097523 | 0.86 | CXCR4 (0.57) | CXCR4SMN1; SMN2KEAP1SIGMAR1POLB | |
| SCHEMBL21799929 | 0.84 | CXCR4 (0.61) | CXCR4SMN1; SMN2KEAP1SIGMAR1POLB | |
| SCHEMBL21799813 | 0.84 | CXCR4 (0.61) | CXCR4SMN1; SMN2KEAP1SIGMAR1POLB | |
| SCHEMBL542926 | 0.84 | CXCR4 (0.61) | CXCR4SMN1; SMN2KEAP1SIGMAR1POLB | |
| SCHEMBL10705415 | 0.84 | CXCR4 (0.61) | CXCR4SMN1; SMN2KEAP1SIGMAR1POLB | |
| SCHEMBL21799944 | 0.84 | CXCR4 (0.61) | CXCR4SMN1; SMN2KEAP1SIGMAR1POLB | |
| SCHEMBL8502191 | 0.84 | CXCR4 (0.61) | CXCR4SMN1; SMN2KEAP1SIGMAR1POLB | |
| SCHEMBL15065195 | 0.84 | CXCR4 (0.55) | CXCR4SMN1; SMN2KEAP1SIGMAR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960556-B2 | Thiadiazole derivatives for the treatment of neuro-degenerative diseases | NV REMYND (BE) | 2011-06-14 | — | — | US | disclosed |
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-06-10 | — | — | US | disclosed |
| EP-2094677-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV Remynd (BE) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008061781-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2008-05-29 | — | — | WO | disclosed |
| EP-0789062-B1 | WATER-ABSORBENT RESIN DISPERSION AND POLYURETHANE COMPOSITION | SANYO CHEMICAL IND LTD (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-5994421-A | CROSSLINKING | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 1999-11-30 | — | — | US | disclosed |
| EP-0789062-A1 | WATER-ABSORBENT RESIN DISPERSION AND POLYURETHANE COMPOSITION | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 1997-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | SNCA, PARK7, PRNP | CXCR4 3145/4885SMN1; SMN2 8/4885KEAP1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.